Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-02
2007-01-02
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S654000, C548S503000, C564S503000
Reexamination Certificate
active
10472741
ABSTRACT:
The present invention provides compounds of formula Ipharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HT6receptor. The present invention further provides a method of treating disorders associated with 5-HT6receptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.
REFERENCES:
patent: 6187805 (2001-02-01), McAllister et al.
patent: 6750348 (2004-06-01), Bridger et al.
patent: 2 085 006 (1982-04-01), None
patent: WO 93/11761 (1993-06-01), None
patent: WO 99/16746 (1999-04-01), None
patent: WO 00/34242 (2000-06-01), None
patent: WO-0042045 (2000-07-01), None
Database Crossfire Beilstein Online! Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main DE; (3-ethoxy-benzyl)-(3-ethoxy-phenethyl)-amine), Database accession No. 3365863: XP002209140.
Tsai et al. “N1-(Benzenesulfonyl)tryptamines as Novel 5-HT6 Antagonists” Bioorganic & Medicinal Chemistry Letters 2000, 2295-2299.
Bromidge et al. “Phenyl Benzenesulfonamides are Novel and Selective 5-HT6 Antagonists: Identification of . . . ” Bioorganic & Medicinal Chemistry Letters, 2001, 55-58.
Isaac et al. “6-Bicyclopiperazinyl-1-arylsulfonylindoles and 6-Bicyclopiperidinyl-1-arylsulfonylindoles Derivatives as Novel, Potent, and Selective 5-HT6 Receptor Antagonists” Bioorganic & Medicinal Chemistry Letters 2000, 1719-1721.
Ide et al. “Pharmacologically Active Compounds from Alkoxy-B-phenylethylamines” Journal of the American Chemical Society 1937, 726-731.
Database Crossfire Beilstein Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(4-ethoxy-phenethyl)-amine), IDE, BUCK: Database accession No. 3365864; XP002209139.
Database Crossfire Beilstein Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(3-ethoxy-phenethyl)-amine), Database accession No. 3365863; XP002209140.
Database Crossfire Beilstein Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(2-ethoxy-henethyl)-amine), IDE, BUCK: Database accession No. 3380345; XP002209141.
Barton, et al., “886. Phenol Oxidation and Biosynthesis. Part VI. The Biogenesis of Amaryllidaceae Alkaloids,” Barton, Kirby, Taylor and Thomas, pp. 4545-4558 (1963).
Vinogradova, et al., “Synthesis Based on b-Phenylethylamines. IV. Synthesis and Antiarrhythmic Activity of Substituted Phenylalkylamines and N-Benzyltetrahydroisoquinolines,” vol. 29, No. 3, pp. 259-414 (1993).
Vinogradova, et al., “Syntheses Based on b-Ethylamines. VIII. Synthesis of Substituted 2-Benzyltetrahydroisoquinolines and Their Influence on Bile Secretion,” vol. 30, No. 3, pp. 368-370 (1994).
ACS Chemcats 2000:1020106, Order No. STOCK1S-08349, CAS Registry No. 302795-49-9.
Bos et al., “5-HT6 receptor antagonists: lead optimization and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides,”Eur J. Med. Chem.,vol. 36, pp. 165-178 (2001).
Bourson et al., “Determination of the Role of the 5-ht6 Receptor in the Rat Brain: A Study using Antisense Oligonucleotides,”J. of Pharm. And Experimental Therapeutics,vol. 274, No. 1, pp. 173-180 (1995).
Meneses, Alfredo, “Effects of the 5-HT6 receptor antagonist Ro 04-6790 on learning consolidation,”Behavioral Brain Research,vol. 118, pp. 107-110 (2001).
Rogers et al., “5-HT6 receptor antagonists enhance retention of a water maze task in the rat,”Psychopharmacology,vol. 158, pp. 114-119 (2001).
Chen Zhaogen
Cohen Michael Philip
Fisher Matthew Joseph
Giethlen Bruno
Gillig James Ronald
Combs Tonya L.
Desai Manisha A.
Eli Lilly and Company
Kosack Joseph R.
McGraw Elizabeth A.
LandOfFree
N-(2-Arylethyl) benzylamines as antagonists of the 5-HT 6... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-(2-Arylethyl) benzylamines as antagonists of the 5-HT 6..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(2-Arylethyl) benzylamines as antagonists of the 5-HT 6... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3721000